Is it appropriate to report both codes 86038 and 86039 when an antinuclear antibodies (ANA) test is performed by immunofluorescence assay (IFA) using crithidia luciliae? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article explains a CPT coding question involving antinuclear antibody testing performed by immunofluorescence assay and the related reporting of testing components. It is aimed at coding professionals, billing staff, and other healthcare revenue cycle readers who need to understand how the article frames CPT guidance, cross-references to other CPT entries, and the impact of payer-specific policy differences. The discussion also touches on professional component billing and the distinction between CPT guidance and Medicare or third-party payer requirements.
Why This Topic Matters
Accurate reporting of laboratory and pathology services depends on knowing which CPT entries apply, whether related references redirect the coder elsewhere, and when payer rules may differ from standard coding guidance. This article helps readers identify the scope of the coding question and the broader reimbursement context before applying payer-specific policies.
What You Will Learn
- How the article frames a CPT reporting question for ANA testing
- How related CPT cross-references are discussed in the context of immunofluorescence methods
- How professional component reporting is presented in relation to laboratory interpretation
- How the article distinguishes CPT guidance from payer-specific reimbursement policies
Who Should Read This
- Medical coders
- Coding auditors
- Billing specialists
- Laboratory billing staff
- Revenue cycle professionals
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com